|
Global Respiratory Syncytial Virus Partnering 2012-2018 |
Sep 1 2018 |
150 |
Global |
$1,995.00 |
|
|
Global Congestive Heart Failure Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Asthma Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Cardiovascular Partnering 2012-2018: Deal trends, players and financials |
Sep 1 2018 |
500 |
Global |
$2,995.00 |
|
|
Global Cystic Fibrosis Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Leukemia Partnering 2012 to 2018 |
Sep 1 2018 |
150 |
Global |
$1,995.00 |
|
|
Global Age-related Macular Degeneration Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Cancer Vaccine Partnering 2012-2018: Deal trends, players, financials and forecasts |
Sep 1 2018 |
200 |
Global |
$2,995.00 |
|
|
Global Neuropathy Partnering 2012 to 2018 |
Sep 1 2018 |
150 |
Global |
$1,995.00 |
|
|
Global Musculoskeletal Partnering 2012-2018: Deal trends, players and financials |
Sep 1 2018 |
1000 |
Global |
$2,995.00 |
|
|
Global Allergy Partnering 2012 to 2018 |
Sep 1 2018 |
150 |
Global |
$1,995.00 |
|
|
Global Human Papilloma Virus Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Hypertension Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Smoking Cessation Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Autoimmune Partnering 2012-2018: Deal trends, players and financials |
Sep 1 2018 |
700 |
Global |
$2,995.00 |
|
|
Global Ulcerative Colitis Partnering 2012-2018 |
Sep 1 2018 |
150 |
Global |
$1,995.00 |
|
|
Global Gastric Cancer Partnering 2012 to 2018 |
Sep 1 2018 |
150 |
Global |
$1,995.00 |
|
|
Global Musculoskeletal Symptoms Partnering 2012-2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
Global Parkinson's Disease Partnering 2012 to 2018 |
Sep 1 2018 |
150 |
Global |
$1,995.00 |
|
|
Global Viral Partnering 2012-2018: Deal trends, players and financials |
Sep 1 2018 |
500 |
Global |
$2,995.00 |
|
|
Global Systemic Lupus Erythematosus Partnering 2012 to 2018 |
Sep 1 2018 |
100 |
Global |
$1,995.00 |
|
|
The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players |
May 4 2018 |
140 |
Global |
$2,995.00 |
|
|
Acne Vulgaris - Epidemiology Forecast to 2026 |
Mar 1 2018 |
37 |
Global |
$3,995.00 |
|
|
OpportunityAnalyzer: Late - Stage Chronic Kidney Disease - Opportunity Analysis and Forecasts to 2026 |
Dec 31 2017 |
195 |
Global |
$10,995.00 |
|
|
PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2026 |
Dec 20 2017 |
280 |
Global |
$10,995.00 |
|
|
PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026 |
Dec 20 2017 |
185 |
Global |
$10,995.00 |
|
|
Warner Chilcott Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
|
Global Injectable Drug Delivery Partnering 2010-2017: Deal trends, players, financials and forecasts |
Sep 1 2017 |
230 |
Global |
$1,995.00 |
|
|
Global Hepatitis Partnering 2010 to 2017 |
Sep 1 2017 |
150 |
Global |
$1,495.00 |
|
|
Fresenius Partnering Deals and Alliances 2010 to 2017 |
Sep 1 2017 |
100 |
Global |
$1,495.00 |
|
